Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

December 2021

Volume 7, Issue 15

This issue explores doctor deserts, celebrates the 50th anniversary of the National Cancer Act, and more.

Special Collection Image
Reader Responses: What are the treatment options for this patient with aggressive blastoid mantle cell lymphoma and high bilirubin?
You Must Be Present to Win
Editor’s Corner: Ill Communication
Adding All-Trans Retinoic Acid to Low-Dose Rituximab in Corticosteroid-Resistant or Relapsed ITP
Liso-Cel Shows Promising Safety and Efficacy in Relapsed/Refractory CLL/SLL
Comparing AHCT Versus CAR T-Cell Therapy in Relapsed DLBCL
How Long Is the Indolent Preclinical Phase of High-Risk CLL?
ASH Remembers Joseph Bertino, National Academy of Medicine Elects Helen Heslop, and more
ASH Congratulates Three New ASH Executive Committee Members, and more
POD24 Predicts Poor Prognosis in Follicular Lymphoma
Finding a Common Transcriptional Drive Across Bone Marrow Failure Subtypes
Pembrolizumab Versus Brentuximab Vedotin in Relapsed/Refractory cHL
Identifying Nosology of Splenic Marginal Zone B-Cell Lymphoma to Improve Targetable Therapy Development
Therapeutic Heparin May Benefit Moderately Ill, Hospitalized Patients With COVID-19
Daratumumab Maintenance Improves PFS in Newly Diagnosed Myeloma
Comparing Apixaban to Warfarin for Reducing Stroke Risk in Thrombotic Antiphospholipid Syndrome
Frontline, Time-Limited Acalabrutinib, Venetoclax, and Obinutuzumab Active in Treatment-Naïve CLL
Modified-Dose Anticoagulation in Patients With Cancer, VTE, and Thrombocytopenia
Pulling Back the Curtain: George Karp, MD, and Rebecca Karp Leaf, MD
A Piggy pASHion

Advertisement

Connect with us:

CURRENT ISSUE
Mid-November 2022

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright ©2022 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement